Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and ...

JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera” or the "Company”), a leader in the ...

Article updated to correct “Jim Krieg” to “James Kreig” MALVERN, PENNSYLVANIA / ACCESS Newswire / November 12, 2025 / Pace ...

FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencin ...

Presidents Donald J. Trump (United States) and Javier Milei (Argentina) announced on Thursday a “Framework for a Reciprocal ...

Vero expands internationally with its first Australian client, bringing next-generation systems to support the expansion of Soda Capital’s wholesale financing platform. NEW YORK, NY AND BRISBANE, ...

An artificial intelligence tool that can predict a patient’s health has been created by Victorian researchers, introducing a ...

Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy ...